Why did Merck buy Acceleron?
“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” said Rob Davis, chief executive officer and president, Merck.
How much did Merck pay for Acceleron?
$11.5 billion
Merck MRK –2.15% said it completed its $11.5 billion acquisition of Acceleron Pharma XLRN –0.52% , disappointing some investors in the biotech who had hoped for a better deal, and giving Merck one more arrow in its quiver as it prepares for the patent on its megablockbuster cancer therapeutic Keytruda to expire later …
Who owns Acceleron?
Merck & Co.Merck Sharp & Dohme Corp.
Acceleron Pharma/Parent organizations
Who is buying acceleron?
Merck & Co
Sept 30 (Reuters) – Merck & Co (MRK. N) said on Thursday it would buy Acceleron Pharma Inc (XLRN. O) for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
What drugs does acceleron make?
Acceleron has four drugs in clinical trials, and one in preclinical development.
- Luspatercept (ACE-536) for anemia.
- Sotatercept (ACE-011) for kidney disease.
- Dalantercept (ACE-041) for kidney cancer.
- ACE-083 for muscular disorders.
Who did Merck just acquire?
(Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.
Where is acceleron located?
Cambridge, Massachusetts
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such …
What company is Merck buying?
June 17 (Reuters) – Drugmaker Merck & Co (MRK. N) is considering buying cancer-focused biotech company Seagen Inc (SGEN. O), the Wall Street Journal reported on Friday, citing people familiar with the matter.
Who did Merck buy out?
If you want Merck to snap you up for nearly $2 billion, all you have to do is play hardball. That’s according to a new Securities and Exchange Commission (SEC) filing from the Big Pharma, which details how Merck bought up little Pandion for $1.9 billion last month.
Who founded Acceleron Pharma?
1. John Knopf, 64, founded Acceleron (Nasdaq: XLRN) in 2003 to focus on a protein in the body that has been largely overlooked, known as the transforming growth factor beta protein superfamily. Today the company has a drug in late-stage trials for two rare blood diseases, beta-thalassemia and myelodysplastic syndromes.
What company did Pfizer buy?
Arena Pharmaceuticals
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
What is CD24Fc?
CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) (SAC-COVID) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
How many employees does Acceleron Pharma have?
225
Acceleron Pharma
| Industry | Biotechnology |
|---|---|
| Headquarters | Cambridge, Massachusetts , United States |
| Key people | Habib Dable (CEO) Steve Ertel (COO) Matt Sherman (CMO) Kevin McLaughlin (CFO) Francois Nader (Chairman) |
| Revenue | $74.5 million for FY2017 |
| Number of employees | 225 (Dec 2019) |
Is Merck going to split?
Merck and (MRK) has 6 splits in our Merck and stock split history database. The first split for MRK took place on June 01, 1972. This was a 2 for 1 split, meaning for each share of MRK owned pre-split, the shareholder now owned 2 shares….
| MRK Split History Table | |
|---|---|
| Date | Ratio |
| 06/03/2021 | 1048 for 1000 |
Will Merck stock go up?
The accelerated from less than 3% growth in 2020. For 2022, Merck calls for $56.9 billion to $58.1 billion in sales, up 18% at the midpoint. The company also expects to earn $7.24-$7.36 per share, minus some items. Analysts call for adjusted earnings of $7.38 per share and $57.95 billion in sales.